Compare CCAP & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCAP | NPCE |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.2M | 514.3M |
| IPO Year | N/A | 2021 |
| Metric | CCAP | NPCE |
|---|---|---|
| Price | $14.59 | $16.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $16.50 | ★ $18.00 |
| AVG Volume (30 Days) | 253.8K | ★ 270.1K |
| Earning Date | 02-18-2026 | 03-03-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $172,891,000.00 | $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $13.03 | $7.56 |
| 52 Week High | $20.19 | $18.98 |
| Indicator | CCAP | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 58.95 |
| Support Level | $14.28 | $15.68 |
| Resistance Level | $14.93 | $17.90 |
| Average True Range (ATR) | 0.34 | 0.94 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 63.73 | 69.78 |
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.